Nivolumab-induced diffuse type 2 rhinosinusitis: A case report.

IF 2.3 4区医学 Q3 ALLERGY

Asian Pacific journal of allergy and immunology Pub Date : 2025-03-01 DOI:10.12932/AP-240721-1196

Firas Kassem, Yossi Rosman, Ilan Blau, Ben Nageris, Anna Zakharov, Ameen Biadsee

{"title":"Nivolumab-induced diffuse type 2 rhinosinusitis: A case report.","authors":"Firas Kassem, Yossi Rosman, Ilan Blau, Ben Nageris, Anna Zakharov, Ameen Biadsee","doi":"10.12932/AP-240721-1196","DOIUrl":null,"url":null,"abstract":"Background: Nivolumab, an immune checkpoint inhibitor is used to treat advanced metastatic malignancies. Data showed that nivolumab can cause exacerbated response of T-Helper 2 cells and lead to airway inflammation.Objective: To present the upper airway findings of a 69-year-old woman after treatment with nivolumab.Methods: Case report.Results: A 69-year old woman with no history of chronic rhinosinusitis developed complaints of nasal congestion, rhinorrhea, sneezing, and anosmia. These symptoms started after one year of treatment with nivolumab. Pale polyps were observed on fiberoptic endoscopy examination. A gradual increase in eosinophil blood counts was noted. On histopathology, heavy infiltrates of eosinophils were seen in the tissue.Conclusions: Nivolumab is used to treat various advanced metastatic malignancies, with a good safety profile. Nevertheless, physicians must be alert to the possibility of evolving type II inflammation in patients, as appropriate therapy can be provided to improve their quality of life.","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"93-96"},"PeriodicalIF":2.3000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific journal of allergy and immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12932/AP-240721-1196","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Nivolumab, an immune checkpoint inhibitor is used to treat advanced metastatic malignancies. Data showed that nivolumab can cause exacerbated response of T-Helper 2 cells and lead to airway inflammation.

Objective: To present the upper airway findings of a 69-year-old woman after treatment with nivolumab.

Methods: Case report.

Results: A 69-year old woman with no history of chronic rhinosinusitis developed complaints of nasal congestion, rhinorrhea, sneezing, and anosmia. These symptoms started after one year of treatment with nivolumab. Pale polyps were observed on fiberoptic endoscopy examination. A gradual increase in eosinophil blood counts was noted. On histopathology, heavy infiltrates of eosinophils were seen in the tissue.

Conclusions: Nivolumab is used to treat various advanced metastatic malignancies, with a good safety profile. Nevertheless, physicians must be alert to the possibility of evolving type II inflammation in patients, as appropriate therapy can be provided to improve their quality of life.

查看原文本刊更多论文

Nivolumab引发的弥漫性2型鼻窦炎：病例报告

背景：Nivolumab是一种免疫检查点抑制剂，用于治疗晚期转移性恶性肿瘤。数据显示，尼妥珠单抗可引起T-Helper 2细胞反应加剧，导致气道炎症：介绍一名69岁女性在接受尼妥珠单抗治疗后的上呼吸道检查结果：方法：病例报告：结果：一名没有慢性鼻炎病史的 69 岁女性出现了鼻塞、鼻出血、打喷嚏和嗅觉障碍等症状。这些症状是在使用尼妥珠单抗治疗一年后开始出现的。纤维内窥镜检查发现了浅色息肉。嗜酸性粒细胞计数逐渐增加。组织病理学检查显示，组织中出现大量嗜酸性粒细胞浸润：Nivolumab可用于治疗各种晚期转移性恶性肿瘤，具有良好的安全性。结论：Nivolumab 可用于治疗各种晚期转移性恶性肿瘤，具有良好的安全性，但医生必须警惕患者可能出现的 II 型炎症，因为适当的治疗可以改善患者的生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian Pacific journal of allergy and immunology 医学-过敏

CiteScore

12.80

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The Asian Pacific Journal of Allergy and Immunology (APJAI) is an online open access journal with the recent impact factor (2018) 1.747 APJAI published 4 times per annum (March, June, September, December). Four issues constitute one volume. APJAI publishes original research articles of basic science, clinical science and reviews on various aspects of allergy and immunology. This journal is an official journal of and published by the Allergy, Asthma and Immunology Association, Thailand. The scopes include mechanism, pathogenesis, host-pathogen interaction, host-environment interaction, allergic diseases, immune-mediated diseases, epidemiology, diagnosis, treatment and prevention, immunotherapy, and vaccine. All papers are published in English and are refereed to international standards.